I
218.05
-5.81 (-2.59%)
| Previous Close | 223.85 |
| Open | 224.88 |
| Volume | 1,529,436 |
| Avg. Volume (3M) | 861,567 |
| Market Cap | 18,001,664,000 |
| Price / Earnings (TTM) | 24.23 |
| Price / Earnings (Forward) | 14.60 |
| Price / Sales | 2.03 |
| Price / Book | 1.72 |
| 52 Weeks Range | |
| Earnings Date | 23 Oct 2024 |
| Profit Margin | 9.00% |
| Operating Margin (TTM) | 14.45% |
| Diluted EPS (TTM) | 9.00 |
| Quarterly Revenue Growth (YOY) | -1.20% |
| Quarterly Earnings Growth (YOY) | 20.40% |
| Total Debt/Equity (MRQ) | 37.00% |
| Current Ratio (MRQ) | 1.34 |
| Operating Cash Flow (TTM) | 1.39 B |
| Levered Free Cash Flow (TTM) | 1.07 B |
| Return on Assets (TTM) | 4.17% |
| Return on Equity (TTM) | 7.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | ICON plc | Bearish | Bearish |
AIStockmoo Score
2.1
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 2.13 |
|
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 101.13% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 350.00 (Evercore ISI Group, 60.52%) | Buy |
| Median | 280.00 (28.41%) | |
| Low | 225.00 (Baird, 3.19%) | Hold |
| Average | 282.78 (29.69%) | |
| Total | 7 Buy, 2 Hold | |
| Avg. Price @ Call | 229.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 18 Dec 2024 | 284.00 (30.25%) | Buy | 204.40 |
| 28 Oct 2024 | 295.00 (35.29%) | Buy | 230.50 | |
| Baird | 20 Nov 2024 | 225.00 (3.19%) | Hold | 203.67 |
| 25 Oct 2024 | 249.00 (14.20%) | Hold | 220.47 | |
| Leerink Partners | 19 Nov 2024 | 255.00 (16.95%) | Buy | 195.60 |
| 25 Oct 2024 | 270.00 (23.83%) | Buy | 220.47 | |
| Barclays | 25 Oct 2024 | 275.00 (26.12%) | Buy | 220.47 |
| 15 Oct 2024 | 330.00 (51.34%) | Buy | 294.87 | |
| Goldman Sachs | 25 Oct 2024 | 280.00 (28.41%) | Buy | 220.47 |
| JP Morgan | 25 Oct 2024 | 280.00 (28.41%) | Buy | 220.47 |
| TD Cowen | 25 Oct 2024 | 285.00 (30.71%) | Buy | 220.47 |
| Redburn Atlantic | 14 Oct 2024 | 311.00 (42.63%) | Hold | 296.55 |
| Evercore ISI Group | 08 Oct 2024 | 350.00 (60.52%) | Buy | 287.56 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Dec 2024 | Announcement | ICON Announces Appointment of Chief Operating Officer |
| 05 Dec 2024 | Announcement | ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption |
| 13 Nov 2024 | Announcement | ICON plc to Present at the Jefferies London Healthcare Conference |
| 23 Oct 2024 | Announcement | ICON Reports Third Quarter 2024 Results |
| 27 Sep 2024 | Announcement | ICON plc Schedules Third Quarter 2024 Earnings Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |